MedWatch

Kåre Schultz leaves Lundbeck

Kåre Schultz resigns his job at the helm of Danish drug group Lundbeck to become CEO of another international pharma group. At the same time, Lundbeck also loses its chief commercial officer.

Adm. direktør for Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles